iBio, Inc. (IBIO) stock
IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
$0.73−0.03 (-4.00%)
Close on Nov 13, 2026Market cap $47.05MP/E –Yield –
iBio gross margin
Gross margin is gross profit as a percentage of revenue.
iBio's gross margin for the twelve months ending Jun 30, 2022 was 115.0%. For fiscal 2022 it was 115.0%, against 38.3% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2022 | Jun 30, 2022 | 115.0% | +76.7 |
| FY2021 | Jun 30, 2021 | 38.3% | −18.7 |
| FY2020 | Jun 30, 2020 | 57.1% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | 105.3% | +31.4 |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | 61.9% | −11.4 |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | 35.6% | +25.1 |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | 70.1% | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | 73.9% | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | 73.3% | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | 10.4% | – |
See a number that looks wrong?